Status:
UNKNOWN
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer
Lead Sponsor:
Assiut University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-80 years
Brief Summary
Checkpoint proteins regulate the immune system; breast cancer cells exploit the up-regulation or down-regulation of these proteins to evade anti-tumour immune responses . It is now well recognized tha...
Detailed Description
Breast cancer is the most common malignant tumour and the leading cause of cancer-associated mortality among women .Although comprehensive therapies exist, patient response to the treatments significa...
Eligibility Criteria
Inclusion
- Female patients with breast cancer aged \> 18 years attending the Medical Oncology department of South Egypt Cancer Institute
Exclusion
- Patients on chemotherapy
- A history of any other malignancy
- known (HIV) and/or hepatitis B or hepatitis C viruses,
- pregnancy or breast feeding
- patients or controls that refuse to be a part of the study.
Key Trial Info
Start Date :
May 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT06169007
Start Date
May 1 2024
End Date
December 1 2025
Last Update
December 20 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.